Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Immunovant ends cutaneous lupus program after phase 2 flop

Immunovant ends cutaneous lupus program after phase 2 flop

September 23, 2026Posted inBiotechnology

Immunovant has stopped development of IMVT-1402 in cutaneous lupus erythematosus after failing a midphase test, closing off one path to market for the anti-FcRn antibody.

Post navigation

Previous Post
Boehringer adds $250M to value of Variant pact by expanding into cardiovascular disease
Next Post
Enveda reaps $311M series E to feed ambition to become a ‘household name’

Recent Posts

  • Encrypted AI Training: Blockchain and Homomorphic Encryption Harden Federated Learning
  • Immunotherapy Reshapes Advanced Liver Cancer Care in Europe, but Access Lags Behind
  • Mother and Baby Do Not Share a Metabolic Fingerprint at Birth, Study Finds
  • Water Molecules Shield Metal-Organic Framework From Ibuprofen’s Strongest Grip
  • Liver Surgery Gives Cats With Rare Tumours a Far Better Prognosis Than Once Thought

Archives

  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top